Home - Gastroenterology Advisor
WEBFDA Alert: Gastroenterology Drug Approvals and New Indications. The FDA approved a biosimilar for inflammatory bowel diseases and issued several new indications for nonerosive GERD, UC, and PFIC.
Clinician Insights on How to Manage Semaglutide-Induced …
WEBSep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
What We Know About Semaglutide Adverse Events and …
WEBSep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
Prior Biologic Therapy Intolerance Linked to Favorable Treatment ...
WEB18 hours ago · Previous biologic therapy intolerance may be associated with improved treatment responses compared with previous biologic failure in patients with inflammatory bowel disease (IBD), according to study results published in the Journal of Crohn’s and Colitis. Researchers analyzed patient-level data from the …
Delayed Endoscopy Linked to Higher Hospitalization in …
WEB2 days ago · The timing of esophagogastroduodenoscopy (EGD) in patients with esophageal food impaction (EFI) does not affect complication rates but is linked to higher hospitalizations when delayed, according to study results published in Digestive Diseases and Sciences.. EFI is a frequent emergency condition, commonly caused by a meat bolus obstruction, with its incidence rising in recent years.
Assessment of Antispasmodics Available in North America for the ...
WEBOct 15, 2021 · Data on the use of antispasmodics available in North America for the treatment of chronic abdominal pain in patients with disorders of gut-brain interaction (DGBI) vary dramatically in safety and efficacy, according to a literature review published in The American Journal of Gastroenterology.Overall, data supporting the use of antispasmodics in this patient population are lacking.
Intestinal Ultrasound for IBD: Clinical Practice Update From the AGA
WEBAug 2, 2024 · The American Gastroenterological Association (AGA) released a clinical practice update in Clinical Gastroenterology and Hepatology about the role of intestinal ultrasound (IUS) in the management of inflammatory bowel diseases (IBDs).. The primary objectives in IBD management are to reverse endoscopically evident inflammation, maintain long-term remission, and to avoid complications.
Novel Drug Tradipitant Effective, Safe for Treatment of Nausea in ...
WEBOct 29, 2021 · Tradipitant appears to be an effective and safe treatment option for gastroparesis symptoms, according to research presented at the American College of Gastroenterology (ACG) 2021 Annual Meeting, held from October 22 to 27, 2021, in Las Vegas, Nevada and virtually.
Tradipitant Relieves Nausea, Other Gastroparesis Symptoms
WEBOct 27, 2022 · Tradipitant is efficacious for relieving nausea and other gastroparesis symptoms. Tradipitant significantly improved nausea and other symptoms in patients with idiopathic and diabetic gastroparesis compared with placebo, according to study results presented at the American College of Gastroenterology (ACG) 2022 Annual Meeting, held from October ...
Treating Helicobacter pylori Infection Reduces Gastric Cancer Risk
WEBJan 27, 2023 · Despite the important role of H pylori eradication in gastric cancer prevention, more than 20% of patients with H pylori infection experience treatment failure, most commonly due to antimicrobial resistance (AMR). 5 For example, clarithromycin and levofloxacin resistance reduces treatment success rates by up to …